Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.76 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685907 | 0.86 | NR1H2 (1.00) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4450601 | 0.84 | NR1H2 (1.00) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4687894 | 0.83 | NR1H2 (0.76) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4693569 | 0.82 | NR1H2 (0.81) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4689082 | 0.82 | NR1H2 (0.78) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4688172 | 0.82 | NR1H2 (0.74) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4688675 | 0.81 | NR1H2 (0.80) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4689452 | 0.81 | NR1H2 (0.72) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL4688716 | 0.81 | NR1H2 (0.72) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 | |
| SCHEMBL5786361 | 0.80 | NR1H2 (0.86) | NR1H2NR1H3MAPTGSK3BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235015-A1 | Pyrrole-2,5-dione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | US | claimed |
| US-7432288-B2 | Pyrrole-2,5-dione derivatives as Liver X receptor modulators | ASTRAZENECA AB (SE) | 2008-10-07 | — | — | US | disclosed |
| EP-1646626-B1 | PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060235015-A1 | Pyrrole-2,5-dione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235015-A1 | Pyrrole-2,5-dione derivatives as liver x receptor modulators | NR1H2, NR1H3, SREBF2 | NR1H2 1/4885NR1H3 2/4885MAPT 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.